Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence

Cardiology in Review
Tien M H NgUri Elkayam

Abstract

Acute heart failure remains a major cause of morbidity, and its treatment requires an increasing investment of the health care system. Whereas success in treating chronic heart failure has been achieved over the last decades, several pharmacological approaches for acute heart failure have been introduced but have failed to demonstrate any clinical benefit. Serelaxin is a recombinant human relaxin-2 vasoactive peptide that causes systemic and renal vasodilation. Data suggest that the clinical benefits may be attributable to a potential combination of multiple actions of serelaxin, including improving systemic, cardiac, and renal hemodynamics, and protecting cells and organs from damage via neurohormonal, anti-inflammatory, antiremodeling, antifibrotic, anti-ischemic, and proangiogenic effects. Recently, a number of clinical trials have demonstrated that serelaxin infusion over 48 hours improved dyspnea with more rapid relief of congestion during the first days after admission for heart failure. In addition, administration of serelaxin diminished cardiac, renal, and hepatic damage, which were associated with improved long-term mortality. Available data support substantial clinical benefits and significant promise for serelaxin as...Continue Reading

References

Aug 26, 1977·Science·C Schwabe, J K McDonald
May 2, 1992·Lancet·H KakourisR J Summers
Jul 31, 1992·Biochemical and Biophysical Research Communications·D G WardM J Cronin
May 1, 1992·Endocrinology·J W WinslowL T Goldsmith
Jun 1, 1990·The Journal of Clinical Endocrinology and Metabolism·D R StewartB L Lasley
Mar 1, 1989·Proceedings of the Society for Experimental Biology and Medicine·G MassicotteJ St-Louis
Apr 1, 1986·Journal of Endocrinological Investigation·G BaniD Bani
Jun 1, 1985·Journal of Endocrinological Investigation·G BaniD Bani
Jan 1, 1974·Archives of Biochemistry and Biophysics·C D Sherwood, E M O'Byrne
Jan 1, 1982·Annals of the New York Academy of Sciences·M EssigG Weiss
Nov 1, 1994·The Journal of Endocrinology·M J Taylor, C L Clark
Oct 1, 1993·The Journal of Pharmacy and Pharmacology·G R Thomas, R Vandlen
Jan 1, 1993·Annual Review of Pharmacology and Toxicology·A M Lefer, D J Lefer
Sep 1, 1995·British Journal of Pharmacology·T Bani-SacchiE Masini
Sep 1, 1996·The Journal of Endocrinology·M TothH Ruskoaho
Jan 1, 1997·General Pharmacology·D Bani
Feb 18, 1999·The Journal of Clinical Investigation·L A DanielsonK P Conrad
Sep 27, 2000·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·L A DanielsonK P Conrad
Jun 8, 2001·The Journal of Clinical Investigation·J NovakK P Conrad
Oct 20, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·T DschietzigK Stangl
Nov 2, 2001·The Journal of Biological Chemistry·Ross A D BathgateGeoffrey W Tregear
Jan 26, 2002·Science·Sheau Yu HsuAaron J W Hsueh
Jul 18, 2002·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Jacqueline NovakKirk P Conrad
Sep 23, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Silvia NistriDaniele Bani
Apr 7, 2004·European Journal of Internal Medicine·Stefan KrügerUwe Janssens
Aug 4, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Thomas DschietzigKarl Stangl
Sep 25, 2004·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Alsadek H BogzilNick Ashton
Feb 11, 2005·European Journal of Heart Failure·Markku KupariJyri Lommi
Jun 9, 2005·Pulmonary Pharmacology & Therapeutics·Carol A TozziDavid J Riley
Jun 16, 2005·Annals of the New York Academy of Sciences·Ishanee MookerjeeChrishan S Samuel

❮ Previous
Next ❯

Citations

Nov 29, 2017·Biomarkers in Medicine·Trabelsi ImenNouira Semir
Oct 24, 2019·Current Molecular Medicine·Rafael Clara MartinsPaulo Castro-Chaves

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Javier Díez
Expert Review of Clinical Pharmacology
Anna Isotta CastriniMarco Metra
Cardiovascular & Hematological Agents in Medicinal Chemistry
Sarmad Said, Debabrata Mukherjee
© 2021 Meta ULC. All rights reserved